News
Advair relabeled to warn of slight risk of bone fractures
WASHINGTON — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of potential decreases in bone mineral density and increased risk of fractures in patients receiving long-term treatment with Advair.
The FDA approved class labeling changes for Advair (fluticasone propionate and salmeterol xinafoate inhalation powder) to advise of new data regarding the risk for decreased bone mineral density (BMD) in patients receiving long-term treatment with inhaled corticosteroids for chronic obstructive pulmonary disease (COPD).
The label for Advair Diskus (GlaxoSmithKline) was updated March 31.
